Last updated: September 24, 2026
Phenobarbital sodium is a mature, low-cost barbiturate used primarily for seizure control, status epilepticus, neonatal seizures, and selected emergency-care applications. Its U.S. market is generic, fragmented, and largely procurement-driven. The drug has no meaningful remaining originator exclusivity, no active biosimilar issue, and limited patent-based pricing power. Revenue is constrained by low unit prices, generic substitution, controlled-substance handling requirements, and competition from levetiracetam, phenytoin/fosphenytoin, valproate, and benzodiazepines.
What is the current market position of phenobarbital sodium?
Phenobarbital sodium is the water-soluble sodium salt of phenobarbital. It is marketed mainly as an injectable hospital product, while oral phenobarbital products are generally supplied as tablets or elixirs under the active ingredient name rather than as a distinct sodium-salt commercial franchise.
| Market factor |
Assessment |
| Product age |
Approximately a century-old active ingredient |
| U.S. regulatory status |
Approved generic prescription drug products |
| Primary dosage form |
Injection, commonly supplied in multiple concentrations |
| Main buyers |
Hospitals, emergency departments, pediatric and neonatal units, wholesalers |
| Drug class |
Barbiturate anticonvulsant and sedative |
| Controlled-substance status |
Schedule IV in the United States |
| Patent leverage |
Minimal to none for the active ingredient |
| Biosimilar exposure |
None; phenobarbital sodium is a small-molecule drug |
| Pricing power |
Low |
| Supply risk |
Higher than the price would suggest because the market is concentrated and hospital inventory is lean |
The product remains clinically relevant where rapid intravenous loading, long half-life, low acquisition cost, or neonatal experience is valued. Its use has declined in many adult seizure protocols because newer agents have more favorable tolerability, interaction, and monitoring profiles.
How large is the phenobarbital sodium market?
No reliable public source reports a consolidated global or U.S. revenue figure for phenobarbital sodium across all manufacturers, dosage forms, channels, and countries. The product is sold by multiple generic manufacturers, repackagers, hospital suppliers, and regional distributors. Public company filings generally combine it with broader generic portfolios.
The financial profile is therefore better measured through market structure than through a single brand revenue number:
- Low acquisition cost limits gross revenue per treatment.
- Hospital contracts and group purchasing organizations determine much of the realized price.
- Injectable supply interruptions can increase short-term value, but they do not create durable pricing power.
- Oral phenobarbital demand is more stable because of chronic epilepsy treatment and veterinary use.
- Manufacturers can earn acceptable returns only through manufacturing scale, reliable supply, efficient regulatory maintenance, and portfolio breadth.
The addressable market is divided between human injectable products, human oral products, international formulations, and veterinary products. These segments have different competitors and demand patterns. A revenue estimate that does not separate those segments is likely to overstate the commercial opportunity for phenobarbital sodium injection.
What is the financial trajectory for phenobarbital sodium?
The long-term trajectory is mature to declining in high-income markets, with episodic volume resilience in hospitals and selected pediatric or neonatal indications.
U.S. financial drivers
| Driver |
Effect on revenue |
| Generic substitution |
Reduces price and manufacturer share |
| Hospital tenders |
Compresses margins |
| Older clinical position |
Limits growth in adult neurology |
| Neonatal and pediatric use |
Supports recurring institutional demand |
| Emergency loading-dose use |
Creates intermittent demand |
| Shortage events |
Can raise volume or price temporarily |
| Controlled-substance compliance |
Raises operating cost and reduces supplier participation |
| Manufacturing concentration |
Increases volatility |
| International access needs |
Supports demand in lower-resource settings |
A manufacturer entering the market should expect a low-price, high-compliance business rather than a specialty-pharmaceutical revenue curve. Growth is more likely to come from winning supply contracts, expanding geographic distribution, or improving manufacturing reliability than from price increases.
The highest-value commercial opportunity is generally not the molecule itself. It is dependable supply of sterile injectable product, especially where hospitals require multiple vial sizes, predictable lead times, and validated storage and distribution procedures.
When does phenobarbital sodium lose exclusivity?
Phenobarbital and phenobarbital sodium are long off-patent. The active ingredient, core therapeutic use, and conventional dosage forms do not have meaningful remaining U.S. exclusivity.
| Exclusivity category |
Current relevance |
| Originator patent |
Expired |
| New chemical entity exclusivity |
Expired decades ago |
| Pediatric exclusivity |
No current commercial significance |
| Orphan-drug exclusivity |
No broad current exclusivity blocking generic supply |
| Formulation exclusivity |
No widely recognized blocking franchise for conventional products |
| Biosimilar exclusivity |
Not applicable |
| Generic approval exclusivity |
Not a durable barrier for this mature product |
A company may hold product-specific patents on a new formulation, delivery system, or combination product. Those rights would protect the modified product, not the conventional phenobarbital sodium market as a whole.
What patents protect phenobarbital sodium?
No active patent estate is generally recognized as protecting conventional phenobarbital sodium injection or standard oral phenobarbital products in the United States. The commercial product is governed primarily by drug approval requirements, manufacturing controls, controlled-substance rules, and supply economics.
Patent analysis should distinguish among:
- Phenobarbital as the active ingredient.
- Phenobarbital sodium injection.
- Oral tablets and elixirs.
- Modified-release or abuse-deterrent formulations.
- Combination products.
- Drug-delivery devices.
- New therapeutic methods involving a defined patient population.
A patent directed to a new delivery system would not ordinarily prevent a generic manufacturer from selling a conventional injectable product outside the patent claims.
What is the Orange Book status of phenobarbital sodium?
The Orange Book lists approved prescription drug products and, where applicable, patent and exclusivity information. Conventional phenobarbital sodium products may appear through approved applications and generic equivalents, but they do not have the type of active listed-patent framework associated with newer branded drugs.
The relevant commercial conclusion is that an ANDA applicant generally faces no significant patent barrier for a conventional phenobarbital sodium product. The principal approval requirements are pharmaceutical equivalence, bioequivalence where applicable, chemistry and manufacturing controls, labeling, facility compliance, and controlled-substance obligations. [1]
Orange Book analysis must be performed at the specific product and application level because not every phenobarbital presentation is marketed by every approved applicant.
Are there Paragraph IV challenges for phenobarbital sodium?
Paragraph IV litigation is unlikely to be commercially significant for conventional phenobarbital sodium because the foundational patents are expired and the market is already supplied by generic products.
A Paragraph IV certification could arise if a company sought approval for a newly patented formulation or method-linked product. That dispute would concern the newer patent claims, not ordinary phenobarbital sodium supply. There is no broad, originator-style Paragraph IV battleground comparable to markets for recently launched branded medicines.
What formulations are protected by phenobarbital sodium patents?
Conventional formulations have limited patent value. Potentially protectable areas include:
- Concentration-specific injectable formulations.
- Stabilized sterile solutions.
- Ready-to-use emergency syringes.
- Extended-release oral dosage forms.
- Pediatric liquid formulations with improved palatability.
- Abuse-deterrent products.
- Combination products.
- Novel delivery systems.
Commercial protection depends on claim scope, written-description support, enablement, prosecution history, and whether generic substitution is possible without practicing the claims. A formulation patent has stronger value when it solves a documented manufacturing, stability, administration, or adherence problem and when the product obtains a distinct regulatory position.
What FDA regulatory issues affect phenobarbital sodium?
Phenobarbital sodium products are subject to the standard U.S. generic-drug framework, but sterile injectable products carry higher execution risk than ordinary oral tablets.
Key regulatory controls
- Sterility assurance and aseptic processing.
- Particulate and endotoxin control.
- Container-closure integrity.
- Concentration and labeling accuracy.
- Compatibility with infusion and injection equipment.
- Controlled-substance recordkeeping.
- Security and diversion controls.
- Postmarketing adverse-event reporting.
- Drug shortage and discontinuation reporting.
Phenobarbital is associated with respiratory depression, sedation, hypotension, drug interactions, and dependence risks. Injectable labeling therefore has direct implications for hospital adoption and procurement. [2]
The FDA’s Drug Shortages database is commercially important because sterile generic injectables can become scarce after manufacturing disruptions, quality observations, facility closures, or raw-material constraints. A shortage can improve the near-term position of an available supplier, but the benefit is unstable and may disappear when competing capacity returns. [3]
Which companies compete with phenobarbital sodium?
Competition comes from two sources: other phenobarbital suppliers and alternative antiseizure medicines.
Direct product competition
The direct market includes generic drug manufacturers, contract manufacturers, repackagers, and hospital suppliers. Supplier participation varies by dosage form, strength, presentation, and geography. A manufacturer’s competitive position depends on whether it controls an FDA-approved application, has reliable sterile capacity, and can meet distributor and hospital qualification standards.
Therapeutic competition
| Alternative |
Competitive impact |
| Levetiracetam |
Common hospital alternative with simpler interaction profile |
| Fosphenytoin/phenytoin |
Competes in status epilepticus and loading-dose protocols |
| Valproate |
Used in selected seizure and status epilepticus settings |
| Lorazepam and midazolam |
Compete for acute seizure termination |
| Carbamazepine and other oral agents |
Compete in chronic seizure management |
Phenobarbital retains advantages in cost, long clinical experience, long half-life, and use in neonatal or resource-constrained settings. Its disadvantages include sedation, respiratory risk, enzyme induction, and drug interactions. Clinical protocols increasingly favor other agents in many adult acute-care settings. [4]
What generic launch risks exist for phenobarbital sodium?
A new generic entrant faces low patent risk but meaningful operational and commercial risk.
Main launch barriers
- Sterile manufacturing capability and inspection readiness.
- Controlled-substance registration and inventory controls.
- Reliable active pharmaceutical ingredient supply.
- Low wholesale prices.
- Limited hospital formulary differentiation.
- Contracting pressure from group purchasing organizations.
- Small market size relative to regulatory maintenance costs.
- Potentially concentrated supplier base.
- Product-specific shortage and discontinuation obligations.
- Need for multiple strengths or vial sizes to win institutional contracts.
The generic launch case is strongest for an established injectable manufacturer that can add phenobarbital sodium to an existing hospital portfolio. It is weaker for a stand-alone entrant that must build distribution, pharmacovigilance, controlled-substance systems, and sterile capacity for one low-priced product.
What patent litigation and settlement agreements affect phenobarbital sodium?
No major current patent-litigation or settlement framework is generally associated with conventional phenobarbital sodium. There is no well-known branded-originator settlement that controls generic entry into the ordinary U.S. market.
Litigation risk is more likely to arise from:
- Product liability claims.
- Manufacturing-quality disputes.
- Contract and supply disputes.
- Controlled-substance compliance matters.
- False Claims Act or government-pricing issues.
- Intellectual-property disputes involving a new formulation or delivery product.
The absence of a major patent dispute does not eliminate regulatory exposure. For an injectable product, FDA manufacturing action or a supply interruption can have greater commercial effect than patent litigation.
How strong is the phenobarbital sodium patent estate?
The conventional patent estate is weak. Its defensive value is minimal because the active ingredient and ordinary products are longstanding generic technologies.
| Patent-strength dimension |
Rating |
| Active-ingredient protection |
None |
| Conventional injection protection |
Weak |
| Standard oral formulation protection |
Weak |
| Novel delivery potential |
Moderate only if genuinely differentiated |
| Method-of-use protection |
Potentially narrow |
| Manufacturing know-how |
More relevant than patent rights |
| Regulatory barriers |
Moderate for sterile products |
| Supply-chain barrier |
Moderate to high for qualified injectable capacity |
Manufacturing know-how, validated sterile processes, quality systems, and customer contracts are more important competitive assets than patents. These assets can be difficult to replicate but generally do not produce the same legal exclusivity as a valid patent.
What licensing deals involve phenobarbital sodium?
No major current licensing transaction is broadly associated with conventional phenobarbital sodium. The product is commonly handled through generic manufacturing, contract manufacturing, distribution, and repackaging arrangements rather than high-value technology licenses.
Potential transaction structures include:
- ANDA acquisition or transfer.
- Contract manufacturing agreements.
- Regional distribution rights.
- Hospital-supply agreements.
- Product portfolio acquisitions.
- Licensing of a novel pediatric, extended-release, or emergency-delivery formulation.
The commercial value of such a deal depends on approved presentations, manufacturing site status, supply history, customer contracts, and shortage performance. A license covering only the conventional active ingredient would have limited strategic value.
How does phenobarbital sodium compare with newer antiseizure drugs?
Phenobarbital is more price-competitive but less differentiated clinically.
| Attribute |
Phenobarbital sodium |
Levetiracetam |
Fosphenytoin/phenytoin |
| Patent position |
Expired |
Largely generic in many markets |
Generic |
| Acquisition cost |
Very low |
Higher than phenobarbital in many settings |
Variable |
| Sedation |
Significant |
Generally lower |
Moderate |
| Drug interactions |
Significant enzyme induction |
Relatively limited |
Significant |
| Neonatal experience |
Established |
Increasing use |
Used in selected cases |
| Hospital supply risk |
Can be concentrated |
Broad generic competition |
Variable |
| Pricing power |
Low |
Low to moderate by presentation |
Low |
Phenobarbital’s commercial durability comes from clinical familiarity and cost, not from innovation or exclusivity.
What geographic markets offer the strongest opportunity?
Demand is likely to remain more resilient in lower-resource and neonatal-care settings where cost, availability, and long clinical experience are decisive. High-income markets remain important for hospital procurement but face stronger substitution from newer antiseizure agents.
Geographic expansion requires country-specific review of:
- Marketing authorization.
- Controlled-substance scheduling.
- Import and export permits.
- Local pharmacopoeial requirements.
- Pediatric and neonatal labeling.
- Public tender rules.
- Reference pricing.
- Local manufacturing or localization requirements.
- Serialization and traceability rules.
A supplier with established sterile capacity and regulatory registrations in multiple countries can improve utilization of existing manufacturing assets. The opportunity is operational rather than patent-driven.
What is the outlook for phenobarbital sodium revenue?
The base-case outlook is stable-to-declining revenue in mature markets, with intermittent upward movements caused by shortages, contract wins, or increased neonatal and emergency use. A sustained increase would require one of four developments:
- A major competitor exits the market.
- A supplier gains a durable hospital contract position.
- A differentiated formulation obtains regulatory and commercial uptake.
- Demand expands in underpenetrated international markets.
Price-led growth is unlikely to persist. The product’s financial profile favors dependable cash generation for an efficient generic operator, not high-growth pharmaceutical investment.
Key Takeaways
- Phenobarbital sodium is an old, off-patent generic with no meaningful originator exclusivity.
- Conventional products have limited patent value and little Paragraph IV litigation risk.
- Injectable supply reliability is more important than patent ownership.
- The U.S. market is low-price, hospital-driven, and vulnerable to sterile-manufacturing disruptions.
- Newer antiseizure drugs limit adult growth, but neonatal, emergency, chronic, veterinary, and international demand support continued use.
- Revenue is fragmented across manufacturers and is not reliably disclosed as a standalone product category.
- The best commercial position belongs to manufacturers with approved sterile injectable capacity, controlled-substance systems, broad distribution, and existing hospital contracts.
- A differentiated formulation or delivery system could create value, but conventional phenobarbital sodium does not offer a durable exclusivity platform.
FAQs
Is phenobarbital sodium still profitable for generic manufacturers?
It can be profitable for manufacturers with efficient sterile operations and existing distribution, but standalone economics are weak because prices are low and compliance costs are significant.
Is phenobarbital sodium an orphan drug?
Conventional phenobarbital sodium is not broadly protected by current orphan-drug exclusivity. A specific new indication or formulation would require separate regulatory analysis.
Can a generic company launch phenobarbital sodium without a patent settlement?
Generally, yes, for a conventional product with no blocking patent. The applicant still must satisfy FDA approval, manufacturing, labeling, controlled-substance, and supply requirements.
Does phenobarbital sodium have shortage-driven pricing potential?
Shortages can produce temporary price increases or higher supplier utilization. Those gains are unstable and usually disappear when competing supply resumes.
Is veterinary phenobarbital sodium part of the same market?
Veterinary products are related but should be analyzed separately because they involve different approvals, buyers, formulations, dosing practices, and distribution channels.
References
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2023). Phenobarbital sodium injection prescribing information. FDA/DailyMed labeling.
- U.S. Food and Drug Administration. (2024). Drug shortages: Current and resolved drug shortages and discontinuations. FDA.
- National Institute for Health and Care Excellence. (2022). Epilepsies in children, young people and adults: NICE guideline NG217. NICE.
